Experimental and theoretical characterization of the release kinetic of carvacrol as inclusion complexes with ß-cyclodextrin in poly(lactic acid) and Mater-Bi® processed by supercritical impregnation.

The incorporation of active compounds into polymeric matrices using traditional methods has several drawbacks mainly due to the high volatility and thermal sensitivity of these substances. A solution to this problem could be the incorporation of bioactive compounds forming inclusion complexes as a strategy to improve the chemical stability, bioactivity and achieve controlled release. In this work, ß-cyclodextrin/carvacrol inclusion complex was prepared by spray drying to be incorporated into poly(lactic acid) (PLA) and Mater-Bi® films by supercritical CO2 impregnation. The impregnation process was carried out at pressures of 10, 15 and 20 MPa and at 40 °C. Both polymers showed the highest amount of incorporated inclusion complex at 15 MPa, where the percentage of impregnation varied from 0.6 % to 7.1 % in Mater-Bi® and PLA, respectively. Release tests for PLA films impregnated with inclusion complex showed a slow release of the active compound, which did not reach equilibrium after 350 h under the experimental conditions. This prolonged release was not observed in Mater-Bi® due to the lower incorporation of the inclusion complex. The release rate was described herein by a comprehensive phenomenological model considering the decomplexation kinetics combined with the equilibrium and mass transfer expressions.

Management of the Difficult Stoma.

Fecal ostomy creation is a commonly performed procedure with many indications. Better outcomes occur when preoperative patient education and stoma site marking are provided. Despite a seemingly simple operation, ostomy creation is often difficult and complications are common. Certain risk factors, particularly obesity, are strongly associated with stoma-related complications. The ability to optimize the ostomy and stoma in the operating room and to troubleshoot frequently encountered post-operative stoma-related issues are critical skills for surgeons and ostomy nurses alike.

Eficacia y seguridad de vacunas contra SARS-CoV-2 en pacientes con enfermedades reumatológicas autoinmunes / Efficacy and safety of SARS-CoV-2 vaccines in patients with autoimmune rheumatologic diseases / Eficácia e segurança das vacinas SARS-CoV-2 em pacientes com doenças reumatológicas autoimunes

Los pacientes con enfermedades reumatológicas autoinmunes tienen mayor riesgo de infección por SARS-CoV-2 por factores propios de la enfermedad, así como los derivados por el tratamiento, con el desarrollo de vacunas se ha priorizado la inmunización en este grupo de pacientes, no obstante, la eficacia y seguridad de vacunas contra SARS-CoV-2 no se ha estudiado en esta población por su exclusión en los ensayos clínicos de fase II-III. Objetivo. analizar la eficacia y seguridad de vacunas contra SARS-CoV-2 en pacientes con enfermedades reumatológicas autoinmunes. Metodología. Se realizó una revisión sistemática, usando la declaración PRISMA, como criterios de búsqueda fueron considerados publicaciones portugués, inglés y español, relacionada con la eficacia y seguridad de vacunas contra SARS-CoV-2 durante los últimos 6 años. La búsqueda de artículos se desarrolló en las bases de datos como PubMed, Scopus y ScienceDirect publicados en idiomas inglés, portugués y español publicados durante los últimos 6 años hasta la actualidad. Resultados. Se encontraron 79 artículos, 27 en PubMed, en Google Scholar 52; la cantidad se redujo a 60, eliminando 19 por duplicidad, 27 por resumen de artículo, luego de un análisis exhaustivo del contenido de la información para así obtener un total de 8 artículos para el análisis del estudio. Conclusión. La eficacia de vacunas contra SARS-CoV-2 en pacientes con enfermedades reumatológicas se encuentra reducida, atribuida al uso de glucocorticoides y de terapias inmunosupresoras en las que se destaca rituximab, micofenolato de mofetilo y metotrexato, mientras que la seguridad basada en los efectos adversos es similar a los encontrados en la población general.

Patients with autoimmune rheumatologic diseases have a higher risk of infection by SARS-CoV-2 due to factors inherent to the disease, as well as those derived from treatment. With the development of vaccines, immunization has been prioritized in this group of patients; however, the efficacy and safety of vaccines against SARS-CoV-2 has not been studied in this population due to their exclusion in phase II-III clinical trials. Objective. to analyze the efficacy and safety of vaccines against SARS-CoV-2 in patients with autoimmune rheumatologic diseases. Methodology. A systematic review was performed, using the PRISMA statement, as search criteria were considered Portuguese, English and Spanish publications, related to the efficacy and safety of vaccines against SARS-CoV-2 during the last 6 years. The search for articles was developed in databases such as PubMed, Scopus and ScienceDirect published in English, Portuguese and Spanish published during the last 6 years to date. Results. A total of 79 articles were found, 27 in PubMed, 52 in Google Scholar; the number was reduced to 60, eliminating 19 for duplicity, 27 for article ABSTRACT, after an exhaustive analysis of the content of the information to obtain a total of 8 articles for the analysis of the study. Conclusion. The efficacy of vaccines against SARS-CoV-2 in patients with rheumatologic diseases is reduced, attributed to the use of glucocorticoids and immunosuppressive therapies in which rituximab, mycophenolate mofetil and methotrexate stand out, while safety based on adverse effects is similar to those found in the general population.

Pacientes com doenças reumatológicas autoimunes têm maior risco de infecção pelo SARS-CoV-2 devido a fatores inerentes à doença, bem como àqueles derivados do tratamento. Com o desenvolvimento de vacinas, a imunização tem sido priorizada nesse grupo de pacientes; no entanto, a eficácia e a segurança das vacinas contra o SARS-CoV-2 não foram estudadas nessa população devido à sua exclusão dos ensaios clínicos de fase II-III. Objetivo. Analisar a eficácia e a segurança das vacinas contra o SARS-CoV-2 em pacientes com doenças reumatológicas autoimunes. Metodologia. Foi realizada uma revisão sistemática utilizando a declaração PRISMA, tendo como critério de busca publicações em português, inglês e espanhol relacionadas à eficácia e à segurança de vacinas contra o SARS-CoV-2 nos últimos 6 anos. A busca de artigos foi desenvolvida em bancos de dados como PubMed, Scopus e ScienceDirect, publicados em inglês, português e espanhol, publicados nos últimos 6 anos até o presente. Resultados. Foram encontrados 79 artigos, 27 no PubMed, 52 no Google Scholar; o número foi reduzido para 60, eliminando 19 por duplicidade, 27 por resumo do artigo, após uma análise exaustiva do conteúdo das informações para obter um total de 8 artigos para a análise do estudo. Conclusões. A eficácia das vacinas SARS-CoV-2 em pacientes com doenças reumatológicas é reduzida, atribuída ao uso de glicocorticoides e terapias imunossupressoras, incluindo rituximabe, micofenolato mofetil e metotrexato, enquanto a segurança baseada em efeitos adversos é semelhante à encontrada na população em geral.

[Energy drink consumption patterns and its adverse effects on adolescent health.] / Patrones de consumo de bebidas energéticas y sus efectos adversos en la salud de adolescentes.

OBJECTIVE: Energy drinks generally contain caffeine and other stimulants, commercially aimed at young people. Previous research suggests that its effects on adolescents health are dangerous. The aim of the study was to evaluate the effect of taurine and caffeine consumption from energy drinks on adolescent health and to identify patterns of consumption and, their association with physiological symptoms. METHODS: A cross-sectional study of a convenience sample of students (n=135) aged 16 to 17 years was conducted in the State of Hidalgo, Mexico. A self-administered online questionnaire was used from September to November 2020 to report energy drink consumption patterns, perceived effects, and psychophysiological symptoms. The statistical analysis of questionnaire content was made by interjudges evaluation. A concordance index (Cohen-Fleiss Kappa coefficient) was applied for consumption patterns, bivariate correlation tests, Pearson correlation coefficients for levels (very high, moderate, low) of caffeine and taurine were used in the items applied to the target population and Spearmans rho for physiological and psychological effects. RESULTS: The participants (mean age: 16 years; 57.8% of women) reported having consumed energy drinks at least once. Only 26.7% of adolescents (n=36) reported that they had never consumed. The average consumption of energy drinks was once per month (24.4%). A statistically significant correlation was found between the consumption of drinks with taurine and the physical effects (tremors and chest pain) and caffeinated beverages with psychophysiological (fatigue, excessive urination, insomnia, and feeling of lack of rest). CONCLUSIONS: The study findings indicate associations between energy drink consumption and the presence of adverse psychological and physical symptoms in adolescents.

OBJETIVO: Las bebidas energizantes generalmente contienen cafeína y otros estimulantes, comercialmente dirigidos a los jóvenes. Investigaciones anteriores sugieren que sus efectos sobre la salud en adolescentes son peligrosos. El objetivo del estudio fue evaluar el efecto del consumo de taurina y cafeína de bebidas energizantes en la salud de los adolescentes y establecer los patrones del consumo, así como su asociación con síntomas fisiológicos. METODOS: Se realizó un estudio transversal de una muestra por conveniencia de estudiantes (n=135) de entre 16 y 17 años de edad en el Estado de Hidalgo, México. Se utilizó un cuestionario en línea autoadministrado de septiembre a noviembre de 2020 para informar los patrones de consumo de bebidas energizantes, los efectos percibidos y los síntomas psicofisiológicos. Para el análisis estadístico del contenido por interjueces. Se aplicó índice de concordancia (coeficiente Kappa de Cohen-Fleiss), para patrones de consumo se utilizaron pruebas de correlación bivariada, coeficientes de correlación de Pearson por niveles (muy alto, moderado, bajo) de cafeína y taurina en los ítems aplicados a población objetivo y rho de Spearman para síntomas fisiológicos y psicológicos. RESULTADOS: Los adolescentes estudiados (media de edad: 16 años; 57,8% de mujeres) informaron haber consumido bebidas energizantes al menos una vez. Solo el 26,7% de los adolescentes (n=36) informaron que nunca habían consumido. El consumo promedio de bebidas energizantes fue de una vez por mes (24,4%). Se encontró correlación estadística significativa entre el consumo de bebidas con taurina y los efectos físicos (temblores y dolor en el pecho) y el de bebidas con cafeína con los psicofisiológicos (fatiga, micción excesiva, insomnio y sensación de falta de descanso). CONCLUSIONES: Los hallazgos del estudio indican asociaciones entre el consumo de bebidas energéticas y la presencia de síntomas adversos psicológicos y físicos en los adolescentes.

Patrones de consumo de bebidasenergéticas y sus efectos adversosen la salud de adolescentes / Energy drink consumption patterns and its adverse effects on adolescent health

FUNDAMENTOS: Las bebidas energizantes generalmente contienen cafeína y otros estimulantes, comercialmente dirigidos a los jóvenes. Investigaciones anteriores sugieren que sus efectos sobre la salud en adolescentes son peligrosos. El objetivo del estudio fue evaluar el efecto del consumo de taurina y cafeína de bebidas energizantes en la salud de los adolescentes y establecer los patrones del consumo, así como su asociación con síntomas fisiológicos. MÉTODOS: Se realizó un estudio transversal de una muestra por conveniencia de estudiantes (n=135) de entre 16 y 17 años de edad en el Estado de Hidalgo, México. Se utilizó un cuestionario en línea autoadministrado de septiembre a noviembre de 2020 para informar los patrones de consumo de bebidas energizantes, los efectos percibidos y los síntomas psicofisiológicos. Para el análisis estadístico del contenido por interjueces. Se aplicó índice de concordancia (coeficiente Kappa de Cohen-Fleiss), para patrones de consumo se utilizaron pruebas de correlación bivariada, coeficientes de correlación de Pearson por niveles (muy alto, moderado, bajo) de cafeína y taurina en los ítems aplicados a población objetivo y rho de Spearman para síntomas fisiológicos y psicológicos. RESULTADOS: Los adolescentes estudiados (media de edad: 16 años; 57,8% de mujeres) informaron haber consumido bebidas energizantes al menos una vez. Solo el 26,7% de los adolescentes (n=36) informaron que nunca habían consumido. El consumo pro-medio de bebidas energizantes fue de una vez por mes (24,4%). Se encontró correlación estadística significativa entre el consumo debebidas con taurina y los efectos físicos (temblores y dolor en el pecho) y el de bebidas con cafeína con los psicofisiológicos (fatiga,micción excesiva, insomnio y sensación de falta de descanso).CONCLUSIONES: Los hallazgos del estudio indican asociaciones entre el consumo de bebidas energéticas y la presencia desíntomas adversos psicológicos y físicos en los adolescentes.(AU)

BACKGROUND: Energy drinks generally contain caffeine and other stimulants, commercially aimed at young people. Previousresearch suggests that its effects on adolescents health are dangerous. The aim of the study was to evaluate the effect of taurineand caffeine consumption from energy drinks on adolescent health and to identify patterns of consumption and, their associationwith physiological symptoms. METHODS: A cross-sectional study of a convenience sample of students (n=135) aged 16 to 17 years was conducted in the State ofHidalgo, Mexico. A self-administered online questionnaire was used from September to November 2020 to report energy drink con-sumption patterns, perceived effects, and psychophysiological symptoms. The statistical analysis of questionnaire content was made byinterjudges evaluation. A concordance index (Cohen-Fleiss Kappa coefficient) was applied for consumption patterns, bivariate correlationtests, Pearson correlation coefficients for levels (very high, moderate, low) of caffeine and taurine were used in the items applied to thetarget population and Spearmans rho for physiological and psychological effects. RESULTS: The participants (mean age: 16 years; 57.8% of women) reported having consumed energy drinks at least once. Only26.7% of adolescents (n=36) reported that they had never consumed. The average consumption of energy drinks was once permonth (24.4%). A statistically significant correlation was found between the consumption of drinks with taurine and the physicaleffects (tremors and chest pain) and caffeinated beverages with psychophysiological (fatigue, excessive urination, insomnia, andfeeling of lack of rest). CONCLUSIONS: The study findings indicate associations between energy drink consumption and the presence of adverse psycho-logical and physical symptoms in adolescents.(AU)

Consumption Patterns of Energy Drinks in Adolescents and Their Effects on Behavior and Mental Health: A Systematic Review.

The aim of the current review was to analyze primary studies about energy drink consumption patterns in adolescents and their relationship with mental health. PubMed, PLOS ONE, PsycINFO, and ScienceDirect databases were searched to identify articles related to adverse effects of energy drinks in adolescents and young adults aged 11 to 18 years. Psychological and behavioral measures were based on validated screening tools used in various contexts, and bias was detected in energy drink consumption patterns. In regard to sex, boys consumed more energy drinks than girls, and a strong, positive association was reported between consumption and probability of risky behaviors; tendency for anxiety, depression, and impulsivity; poor academic performance; and sleep disturbances. A progressive increase in consumption was also noted of 25% to 75% within 5 years. Findings suggest that standardized consumption pattern assessment be included in evaluations of mental health to determine potential causal relationships. [Journal of Psychosocial Nursing and Mental Health Services, 60(2), 41-47.].

Occurrence of Vertical Root Fractures after Apical Surgery: A Retrospective Analysis.

INTRODUCTION: Vertical root fractures (VRFs) are among the most frequent causes of tooth loss, mainly of endodontically treated teeth. However, very few data is available about the occurrence of VRFs following apical surgery. METHODS: Patient charts from 864 patients with 1058 teeth treated with apical surgery (September 1999 to December 2018) were retrospectively evaluated, if a VRF had occurred after surgery. The following, possibly influencing factors were analyzed: sex and age, type of treated tooth, primary versus resurgery, technique of root-end preparation, and timepoint of VRF diagnosis. Endpoints were either tooth extraction or the last follow-up. RESULTS: The study cohort (55% women, 45% men) had a mean age of 52.00 ± 13.97 years (range 9-93 years). The overall rate of VRFs after apical surgery was 4% (42 of 1058 teeth). Among these 42 teeth, 33.3% were mandibular first molars and 26.2% were maxillary second premolars. The most frequently affected root was the mesial root of mandibular first molars (28.6%). With regard to the study parameters, significant differences of VRF rates were observed only for the type of tooth treated. CONCLUSIONS: A low VRF rate of 4% was observed in this study. VRFs commonly occurred in maxillary premolars and mandibular molars, with the mesial root of mandibular first molars affected most frequently. This is in line with previous reports about VRFs in endodontically treated teeth without additional apical surgery.

Respuesta a diferentes escenarios y complicaciones hematológicas en COVID-19 / Response to different scenarios and hematological complications in COVID-19.

Las enfermedades infecciosas emergentes y reemergentes son desafíos constantes para la salud pública en todo el mundo. Los casos recientes de neumonía de causa desconocida en Wuhan, China, han llevado al descubrimiento de un nuevo tipo de Coronavirus (2019-nCoV), que son virus de Ácido Ribonucleico (RNA) envueltos, de forma común encontrados en humanos, otros mamíferos y aves, capaces de causar enfermedades respiratorias, entéricas, hepáticas y neurológicas 1. La amenaza a la salud de la infección por Coronavirus 2 asociado al SRAS (SARS-CoV-2) y la enfermedad que produce el mismo llamada Enfermedad por Coronavirus (COVID-19) ya está estable- cida con sus tasas de infección y mortalidad de manera considerable más altas si se lo compara con otros virus respiratorios adquiridos en la comunidad 2. En tal sentido es necesario dar una respuesta por parte de la Unidad Técnica de Hematología en relación a esta pandemia con el ánimo de aportar al manejo integral de estos pacientes, homogeneizar criterios clínicos, lidiar de mejor manera con la incertidumbre en el diagnóstico y tratamiento de COVID-19. El SARS CoV-2 y su enfermedad COVID-19, en la mayoría de pacientes tiene una presentación con síntomas leves. Sin embargo, en el 5% de los casos diagnosticados requerirán de una Unidad de Cuidados Intensivos (UCI)3, ya que presentan Síndrome de Dificultad Respiratoria Aguda (SDRA), shock séptico, Insuficiencia Multiorgánica y coagulopatía hemorrágica, así como trombótica, incluyendo Coagulación Intravascular Diseminada (CID), alcanzado en las salas de UCI una tasa mortalidad por COVID-19 entre el 22% al 62% en algunas series 4. Adicional, se ha observado que el grupo de pacientes con mala evolución presentan un estado hiperinflamatorio, asemejándose al cuadro clínico descrito de una linfohistiocitosis hemofagocítica secundaria, que en este caso sería desencadenada por SARS CoV-2 5. Un grupo de Hematólogos de diferentes hospitales de la ciudad de Quito: Especialidades Carlos Andrade Marín-Instituto Ecuatoriano de Seguridad Social (HECAM-IESS), Metropolitano; y, hospitales de la ciudad de Guayaquil: Teodoro Maldonado Carbo-IESS, Hospital Luis Vernaza y Clínica Gilbert, basados en la evidencia científica disponible y experticia profesional, elaboraron éste protocolo con las recomendaciones según los diferentes escenarios y complicaciones hematológicas.

Emerging and reemerging infectious diseases are constant challenges to public health worldwide. Recent cases of pneumonia of unknown cause in Wuhan, China have led to the discovery of a new type of Coronavirus (2019-nCoV), which are enveloped ribonucleic acid (RNA) viruses, commonly found in humans, other mammals, and birds, capable of cause respiratory, enteric, liver and neurological diseases 1. The health threat of SARS-associated coronavirus 2 (SARS-CoV-2) and the disease that produces it called COVID-19 has already been established with its considerably higher infection and mortality rates compared to other respiratory viruses acquired in the community 2. In this sense, it is necessary to give a response from the Hematology Technical Unit in relation to this pandemic in order to contribute to the comprehensive management of these patients, homogenize clinical criteria, better deal with uncertainty in the diagnosis and treatment of COVID-19. SARS CoV-2 and its disease COVID-19, in the majority of patients have a presentation with mild symptoms. However, in 5% of diagnosed cases they will require an Intensive Care Unit (ICU) 3, since they present Acute Respiratory Distress Syndrome (ARDS), septic shock, Multiple Organ Failure and hemorrhagic coagulopathy, as well as thrombotic, including Coagulation Disseminated Intravascular (DIC), achieved in the ICU wards a mortality rate for COVID-19 between 22% and 62% in some series 4. Additionally, it has been observed that the group of patients with poor evolution present a hyperinflammatory state, resembling the clinical picture of secondary hemopha- gocytic lymphohistiocytosis, which in this case would be triggered by SARS CoV-2 5. The group of Hematologists from the hospitals of the city of Quito: Specialties Carlos Andrade Marín HECAM-IESS, Metropolitano; and, hospitals in the city of Guayaquil: Teodoro Maldonado Carbo-IESS, Luis Vernaza Hospital and Gilbert Clinic, based on the available scientific evidence and professional expertise, prepared this protocol with the recommendations according to the different hematological scenarios and complications.

Obtención e infusión de plasma convaleciente de paciente recuperado de infección COVID-19 para uso compasivo / Obtaining and infusing convalescent plasma from a patient recovered from COVID-19 infection for compassionate use

El 30 de enero de 2020, la Organización Mundial de la Salud (OMS) declara que el brote de Enfermedad por Coronavirus (COVID-19) constituye una Emergencia Sanitaria de Salud de Preocupación Internacional/Public Health Emergencies of International Concern (PHEIC). El 11 de marzo de 2020, la OMS declara la pandemia1,2. El COVID-19 es una enfermedad respiratoria aguda causada por un coronavirus zoonótico de reciente aparición1. Los coronavirus son una familia de virus que se descubrió en la década de los 60 pero cuyo origen es todavía desconocido. Pueden causar enfermedades tanto en animales como en humanos. En los humanos se sabe que varios coronavirus (229E, OC43, NL63 y HUK 1) son responsables del resfriado común y en raras ocasiones se pueden producir infecciones graves de las vías respiratorias inferiores. Dos de los coronavirus causan infecciones en los seres humanos muchos más graves e incluso a veces mortales; estos son: el Coronavirus del Síndrome Respiratorio de Oriente Medio (MERS-CoV), y el Coronavirus tipo 2 asociado al SARS (SARS-CoV), que produce el síndrome respiratorio agudo grave3,4. La pandemia debida al virus SARS-CoV-2 requiere de medidas sanitarias urgentes encaminadas a reducir el riesgo de transmisión de la infección3,4. Al momento, no existe tratamiento eficaz para abordar la enfermedad por SARS-CoV-2 (COVID-19). La OMS emitió un informe que los primeros resultados con el uso de Plasma de Convaleciente (CP) puede ser una modalidad de tratamiento potencialmente útil para el COVID-193-5.En este sentido, se señaló la oportunidad de que los Sistemas Transfusionales de cada país realicen una evaluación de riesgos para calibrar su capacidad de extraer, preparar y almacenar este tipo de donaciones. Esto incluye recursos humanos y suministros críticos adecuados, así como un control exhaustivo de procedimientos e infraestructuras. En este marco, se sugiere el inicio de contactos con los servicios hospitalarios para que colaboren en la selección de pacientes, que habiendo superado la enfermedad del COVID-19, pudieran ser candidatos para donación de plasma sin mermar en sus derechos1. La decisión de desarrollar esta opción requiere una revisión rápida, pero exhaustiva, del agente etiológico o agentes relacionados y la respuesta inmune a ellos para evaluar los posibles beneficios y riesgos de la inmunización pasiva. Los principios generales establecidos en los documentos de posición de la Red de Reguladores de Sangre (BRN) de la OMS sobre el uso de plasma convaleciente, como elemento de respuesta a brotes anteriores de virus emergentes (2017) y como respuesta al Coronavirus del Síndrome Respiratorio de Oriente Medio (2014) siguen siendo aplicables también a esta pandemia de SARS-CoV-26,7. La falta de evidencia clínica concluyente del uso del plasma convaleciente en infección por SARS-CoV-2 no debería ser razón para abandonar el uso del plasma convaleciente. Los ensayos clínicos aleatorios están en curso y los resultados no estarán disponibles durante meses en tanto no hay justificación basada en la evidencia disponible y la ética profesional para negar categóricamente el uso del plasma convaleciente en los hospitales que no participan en un ensayo clínico aleatorio. El siguiente protocolo ha tomado algunas de las recomendaciones del Comité Científico para la Seguridad Transfusional del Ministerio de Sanidad de España Versión 1.0 ­ 26 marzo de 20201. Y ha sido modificado para tratar de adaptarlo a la realidad de nuestra institución.

On January 30, 2020, the World Health Organization (WHO) declared that the COVID-19 outbreak constitutes a public health emergency of international concern (PHEIC). On March 11, 2020, the WHO declared the pandemic1,2. COVID-19 is an acute respiratory disease caused by a newly emerging zoonotic coronavirus1. Coronaviruses are a family of viruses that was discovered in the 1960s but whose origin is still unknown. They can cause disease in both animals and humans. In humans, several coronaviruses (229E, OC43, NL63, and HUK 1) are known to be responsible for the common cold, and serious infections of the lower respiratory tract can rarely occur. Two of the coronaviruses cause much more serious and even sometimes fatal infections in humans; These are: MERS-CoV, as the cause of respiratory syndrome in the Middle East, and SARS-CoV, which produces severe acute respiratory syndrome3,4. The pandemic due to the SARS-CoV-2 virus requires urgent sanitary measures aimed at reducing the risk of transmission of the infection3,4. Currently, there is no effective treatment to address SARS-CoV-2 disease (COVID-19). The WHO issued a report that early results with the use of convalescent plasma (PC) may be a potentially useful treatment modality for COVID-193-5. In this sense, the opportunity for the Transfusion Systems of each country to carry out a risk assessment to gauge their ability to extract, prepare and store this type of donation. This includes adequate critical human resources and supplies, as well as a comprehensive control of procedures and infrastructure. In this framework, it is suggested that contacts with hospital services be initiated so that they collaborate in the selection of patients who, having overcome the COVID-19 disease, may be candidates for plasma donation without diminishing their rights1. The decision to develop this option requires a rapid, but comprehensive, review of the etiologic agent or related agents and the immune response to them to assess the possible benefits and risks of passive immunization. The general principles established in the position papers of the WHO Blood Regulators Network (BRN) on the use of convalescent plasma, as an element of response to previous outbreaks of emerging viruses (2017) and as a response to the syndrome coronavirus respiratory problems of the Middle East (2014) are still applicable to this SARS-CoV-2 pandemic6,7. The lack of conclusive clinical evidence of the use of convalescent plasma in SARS-CoV-2 infection should not be a reason to abandon the use of convalescent plasma. Randomized clinical trials are ongoing and results will not be available for months as there is no justification based on available evidence and professional ethics to categorically deny the use of convalescent plasma in hospitals that do not participate in a randomized clinical trial. The following protocol has taken some of the recommendations of the Scientific Committee for Transfusion Safety of the Spanish Ministry of Health Version 1.0 - March 26, 20201. And it has been modified to try to adapt it to the reality of our institution.

Exploring Serum Transferrin Regulation of Nonferric Metal Therapeutic Function and Toxicity.

Serum transferrin (sTf) plays a pivotal role in regulating iron biodistribution and homeostasis within the body. The molecular details of sTf Fe(III) binding blood transport, and cellular delivery through transferrin receptor-mediated endocytosis are generally well-understood. Emerging interest exists in exploring sTf complexation of nonferric metals as it facilitates the therapeutic potential and toxicity of several of them. This review explores recent X-ray structural and physiologically relevant metal speciation studies to understand how sTf partakes in the bioactivity of key non-redox active hard Lewis acidic metals. It challenges preconceived notions of sTf structure function correlations that were based exclusively on the Fe(III) model by revealing distinct coordination modalities that nonferric metal ions can adopt and different modes of binding to metal-free and Fe(III)-bound sTf that can directly influence how they enter into cells and, ultimately, how they may impact human health. This knowledge informs on biomedical strategies to engineer sTf as a delivery vehicle for metal-based diagnostic and therapeutic agents in the cancer field. It is the intention of this work to open new avenues for characterizing the functionality and medical utility of nonferric-bound sTf and to expand the significance of this protein in the context of bioinorganic chemistry.